EA201000424A1 - Антитела к il-23 - Google Patents

Антитела к il-23

Info

Publication number
EA201000424A1
EA201000424A1 EA201000424A EA201000424A EA201000424A1 EA 201000424 A1 EA201000424 A1 EA 201000424A1 EA 201000424 A EA201000424 A EA 201000424A EA 201000424 A EA201000424 A EA 201000424A EA 201000424 A1 EA201000424 A1 EA 201000424A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen binding
binding proteins
antibodies
prevention
human
Prior art date
Application number
EA201000424A
Other languages
English (en)
Inventor
Гари Питер Бембридж
Джейн Элизабет Кларксон
Джонатан Генри Эллис
Пол Эндрю Хамблин
Джордж КОПСИДАС
Алан Питер Льюис
Рут Макдам
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40378889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201000424(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA201000424A1 publication Critical patent/EA201000424A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к антигенсвязывающим белкам к человеческому IL-23, к содержащим их фармацевтическим препаратам и к применению таких антигенсвязывающих белков в лечении и/или профилактике воспалительных заболеваний, таких как ревматоидный артрит (РА).
EA201000424A 2007-10-05 2008-10-03 Антитела к il-23 EA201000424A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97784107P 2007-10-05 2007-10-05
PCT/EP2008/063289 WO2009043933A1 (en) 2007-10-05 2008-10-03 Il-23 antibodies

Publications (1)

Publication Number Publication Date
EA201000424A1 true EA201000424A1 (ru) 2010-10-29

Family

ID=40378889

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000424A EA201000424A1 (ru) 2007-10-05 2008-10-03 Антитела к il-23

Country Status (16)

Country Link
US (2) US20110206686A1 (ru)
EP (1) EP2205637A1 (ru)
JP (1) JP2011501738A (ru)
KR (1) KR20100097654A (ru)
CN (1) CN101889026A (ru)
AR (1) AR068723A1 (ru)
AU (1) AU2008306850A1 (ru)
BR (1) BRPI0818620A2 (ru)
CA (1) CA2700758A1 (ru)
CL (1) CL2008002952A1 (ru)
EA (1) EA201000424A1 (ru)
MX (1) MX2010003574A (ru)
PE (1) PE20091342A1 (ru)
TW (1) TW200930729A (ru)
WO (1) WO2009043933A1 (ru)
ZA (1) ZA201002275B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10968271B2 (en) 2015-10-30 2021-04-06 Ablynx N.V. Polypeptides against IL-23

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
BR122021026834B1 (pt) 2008-04-25 2022-11-08 Takeda Pharmaceutical Company Limited Anticorpos isolados que se ligam a fcrn, composição farmacêutica que compreende os mesmos e métodos para detectar e para modular fcrn
US8263748B2 (en) 2008-08-27 2012-09-11 Schering Corporation Lyophilized formulations of engineered anti-IL-23p19 antibodies
EP2414393A1 (en) * 2009-04-01 2012-02-08 Glaxo Group Limited Anti-il-23 immunoglobulins
EP2480251A1 (en) 2009-09-21 2012-08-01 Peptinov SAS Carrier conjugates of il-23-peptides and their induced antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN103282382B (zh) 2010-11-04 2017-11-03 勃林格殷格翰国际有限公司 抗il‑23抗体
AU2012262007B2 (en) 2011-06-02 2017-06-22 Takeda Pharmaceutical Company Limited Fc receptor binding proteins
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
EP2866833B1 (en) 2012-06-27 2019-05-15 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
EP2920202B1 (en) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US9708404B2 (en) 2012-12-21 2017-07-18 Seattle Genetics, Inc. Anti-NTB-A antibodies and related compositions and methods
CN105307675A (zh) 2013-03-15 2016-02-03 美国安进公司 使用抗il23抗体治疗克罗恩氏病的方法
JP2016517408A (ja) 2013-03-15 2016-06-16 アムジェン インコーポレイテッド 抗ｉｌ−２３抗体を用いた乾癬の治療方法
EP3789397B1 (en) 2014-05-22 2023-12-06 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
EA202193002A2 (ru) 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
RU2018113694A (ru) 2015-09-17 2019-10-17 Эмджен Инк. Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23
CN109154611B (zh) 2015-12-09 2022-04-08 科尔沃斯制药股份有限公司 人源化抗cd73抗体
CN108472367A (zh) 2015-12-22 2018-08-31 美国安进公司 作为对il23拮抗剂的临床应答的预测因子的ccl20
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2019300491A1 (en) 2018-07-13 2021-03-04 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
JP2022551603A (ja) 2019-10-03 2022-12-12 エータイアー ファーマ， インコーポレイテッド 抗ｎｒｐ２抗体を含む組成物および方法
JP2023509373A (ja) 2019-12-20 2023-03-08 ノヴァロック バイオセラピューティクス， リミテッド 抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法
CN113698480B (zh) * 2021-09-18 2022-07-01 东大生物技术(苏州)有限公司 一组il-23单克隆抗体及其医药用途
WO2023076998A1 (en) * 2021-10-27 2023-05-04 Atyr Pharma, Inc. COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
CN114920830B (zh) * 2022-05-07 2023-05-16 北京大学 Vκ4-1-IgLC多肽及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1759123B (zh) * 2003-03-10 2011-04-13 先灵公司 Il-23激动剂及拮抗剂的用途；相关试剂
EP1896073B1 (en) * 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
MX2008002179A (es) * 2005-08-25 2008-04-22 Lilly Co Eli Anticuerpos anti-il-23.
ES2619845T3 (es) * 2005-08-31 2017-06-27 Merck Sharp & Dohme Corp. Anticuerpos anti-IL-23 diseñados por ingeniería genética

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10968271B2 (en) 2015-10-30 2021-04-06 Ablynx N.V. Polypeptides against IL-23
US11753465B2 (en) 2015-10-30 2023-09-12 Ablynx N.V. Nucleic acids encoding polypeptides against IL-23

Also Published As

Publication number Publication date
MX2010003574A (es) 2010-04-22
JP2011501738A (ja) 2011-01-13
AR068723A1 (es) 2009-12-02
US20090123479A1 (en) 2009-05-14
ZA201002275B (en) 2011-06-29
CL2008002952A1 (es) 2009-10-16
US20110206686A1 (en) 2011-08-25
EP2205637A1 (en) 2010-07-14
AU2008306850A1 (en) 2009-04-09
CN101889026A (zh) 2010-11-17
CA2700758A1 (en) 2009-04-09
WO2009043933A1 (en) 2009-04-09
PE20091342A1 (es) 2009-09-16
BRPI0818620A2 (pt) 2019-09-24
TW200930729A (en) 2009-07-16
KR20100097654A (ko) 2010-09-03

Similar Documents

Publication Publication Date Title
EA201000424A1 (ru) Антитела к il-23
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
EA201590138A1 (ru) Оптимизация антител, которые связывают ген активации лимфоцитов 3 (lag-3), и их применение
WO2008121615A3 (en) Antibody formulation
MY185813A (en) Factor xi antibodies and methods of use
EA200870129A1 (ru) Человеческие антитела против il-23, композиции, способы и применение
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
EA201391457A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA201100694A1 (ru) Антитело к cd38 человека и его применение
EA201290589A1 (ru) Cd127-связывающие белки
ECSP12012272A (es) Proteínas que se unen al tnf-?
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201492149A1 (ru) St2-антигенсвязывающие белки
CL2008000935A1 (es) Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
EA200970586A1 (ru) Антитела к цитомегаловирусу человека (hcmv)
MX2010005871A (es) Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
EA201270662A1 (ru) Связывающие элементы для человеческого цитамегаловируса
TW200801038A (en) Immunoglobulins